Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ketogenic medium-chain triglycerides** are specialized dietary formulations or supplements consisting primarily of medium-chain triglycerides (MCTs), often from sources such as caprylic acid (C8) and capric acid (C10), used to rapidly induce and maintain ketosis for therapeutic purposes. Their key mechanism is the ability to bypass regular fat absorption pathways, being directly transported via the portal vein to the liver, where they convert quickly into ketone bodies. This property enables the body to generate ketones efficiently without the need for strict carbohydrate restriction or fasting. Ketogenic MCTs are mainly used as part of dietary therapies for drug-resistant epilepsy, especially in children, and are being researched for neurodegenerative diseases like Alzheimer's. Compared to traditional ketogenic diets, MCT-based ketogenic regimens allow a higher intake of carbohydrates and protein, improving palatability and adherence, while lowering the risk of certain side effects like hypoglycemia and constipation[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketogenic medium-chain triglycerides.